Geneos therapeutics secures $17 million in series a2 financing to advance personalized cancer immunotherapy platform

Geneos expands its phase ib/iia clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma financing led by flerie invest and dr. ted fjÄllman joins geneos' board of directors plymouth meeting, pa. , march 24, 2022 /prnewswire/ -- geneos therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured $17 million in series a2 financing.
INO Ratings Summary
INO Quant Ranking